Assoc. Prof. Dr. Çağlar Ünal

Meme Kanseri

Akciğer Kanseri

Kolorektal Kanserler

Jinekolojik Kanserler

Moleküler Onkoloji

Ürogenital Kanserler

İmmünoterapi

2007–2013: Uludağ Üniversitesi Tıp Fakültesi

2014–2019: İstanbul (Çapa) Tıp Fakültesi, İç Hastalıkları

2019–2021: İstanbul Florence Nightingale Hastanesi, Tıbbi Onkoloji

2021–2023: İstanbul Kartal Dr. Lütfi Kırdar Eğitim ve Araştırma Hastanesi, Tıbbi Onkoloji

2019: İstanbul Bahçelievler Devlet Hastanesi

2023–2026: İstanbul Haydarpaşa Numune Eğitim ve Araştırma Hastanesi

Özönder Ünal I, Pirincci Aytac M, Özgedik Turhan N, Taylan Y, Ünal Ç, et al. Attachment Styles as Protective and Amplifying Factors in Caregiver Psychological Distress: A Multicenter Cross-Sectional Study in Oncology and Chronic Disease Caregiving. Healthcare (Basel). 2025;13(20):2612. doi:10.3390/healthcare13202612. PMID: 41154290; PMCID: PMC12563351.

Erdoğan İyigün Z, Ozmen T, İlgün S, Nakipoğlu C, Özkurt E, Çelebi F, Ünal Ç, et al. Evaluation of Long-Term Lymphedema Rate in Patients With Subclinical Lymphedema Diagnosed in the Preoperative Period via Bioimpedance. Eur J Breast Health. 2025;21(1):40-45. doi:10.4274/ejbh.galenos.2024.2024-9-5. PMID: 39744892; PMCID: PMC11706125.

Ünal Ç, Azizy A, Karabulut S, Taştekin D, Akyıldız A, Yaşar S, et al. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group. Oncologist.2023;28(10):875-884. doi:10.1093/oncolo/oyad257. PMID: 37676712; PMCID: PMC10546829.

Ünal Ç, Özmen T, Ordu Ç, Uras C, Kara H, Gökmen E, et al. Assessment High-Risk Breast Cancer in Older Patients: A Comparative Analysis of PREDICT Scores and TAILORx Risk Categorization. Eur J Breast Health. 2023;19(4):325-330. doi:10.4274/ejbh.galenos.2023.2023-8-5. PMID: 37795003; PMCID: PMC10546806.

Ünal Ç, Tunçer G, Çopur B, Pilanci KN, Okutur KS, Yararbaş K, et al. Clinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020-2022). Curr Med Res Opin. 2023;39(7):987-996. doi:10.1080/03007995.2023.2223917. PMID: 37300513.

Ünal Ç, Özmen T, Ordu Ç, Pilanci KN, İlgün AS, Gökmen E, et al. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey. Front Oncol. 2023;13:1151733. doi:10.3389/fonc.2023.1151733. PMID: 37448522; PMCID: PMC10338087.

Ünal Ç, Özmen T, İlgün AS, Ordu Ç, Özkurt E, Ak N, et al. MCM-2 Levels as a Potential Biomarker for Predicting High-Risk Breast Cancer Patients According to TAILORx Classification. Breast Cancer (Dove Med Press). 2023;15:659-669. doi:10.2147/BCTT.S421535. PMID: 37674872; PMCID: PMC10478780.

Ünal Ç, Ordu Ç, Özmen T, İlgun AS, Çelebi F, Baysal B, et al. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study. Curr Oncol. 2023;30(10):9217-9229. doi:10.3390/curroncol30100666. PMID: 37887566; PMCID: PMC10605884.

Unal, Caglar, Sezer Saglam. Metastatik Nöroendokrin Karsinom: BT'de Yaygın Nodüler Kalsifikasyonlarla Başvuran Karaciğer Metastazları. Journal of Cancer Research and Therapeutics. 2023.

Unal, C., Selcuk, N. A., Biricik, F. S., Alan, O., Ordu, C., Selvi, O., ... & Saglam, S. Metastatik Nöroendokrin Tümörlerde Lutetium-177 DOTATATE Peptid Reseptör Radyonüklid Tedavisinin (PRRT) Klinik Etkisinin Değerlendirilmesi: Türkiye'den Çok Merkezli Gerçek Yaşam Verileri. 2023.

Unal C, Ozonder Unal I, Ordu C. Küresel Kriz Dönemlerinde Kanser Hastalarının Baş Etme Stratejileri ve Sosyal Desteklerinin Araştırılması. J Ist Faculty Med. 2023;86(4):345-353. doi: 10.26650/IUITFD.1326105.

Ünal Ç ve Sağlam S. Metronomik Temozolomid (mTMZ) ve Bevacizumab — Metastatik Nöroendokrin Tümörlerin (NET) Tedavisinde Güvenli ve Etkili Yeni Bir Yaklaşım: Tek Merkez Deneyimi. Cancers. 2023;15(23):5688.

Hacioglu MB, Erdogan B, Bardakcı M, Algın E, Gulbagcı B, Hacibekiroglu I, et al.; Ünal Ç, et al. Major and minor salivary gland cancers: A multicenter retrospective study. Head Neck. 2023;45(7):1643-1653. doi:10.1002/hed.27376. PMID: 37084179.

Özönder Ünal I, Ünal C, Duymaz T, Ordu C. COVID-19 Pandemisi Sırasında Kanser Hastalarında Psikolojik Esneklik, Öz-Şefkat ve Travma Sonrası Gelişim Arasındaki İlişki. Support Care Cancer. 2023 Jun 29;31(7):428. doi: 10.1007/s00520-023-07891-4. PMID: 37380871.

Ozmen V, Ordu C, Ilgun AS, Ünal Ç, Soybir G, Erdogan Z, et al. The effects of vitamin D replacement on pathological complete response (pCR) in breast cancer patients receiving neoadjuvant systemic chemotherapy (NAC). Breast J. 2021;27(12):902-905. doi:10.1111/tbj.14299. PMID: 34806247.

Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S, et al.; Ünal Ç, et al. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. Int J Cancer. 2024;154(4):692-700. doi:10.1002/ijc.34749. PMID: 37818966.

Akyildiz A, Guven DC, Koksal B, Karaoglan BB, Kivrak D, Ismayilov R, et al.; Ünal Ç, et al. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG). Eur Arch Otorhinolaryngol.2024;281(9):4991-4999. doi:10.1007/s00405-024-08744-4. PMID: 38795147; PMCID: PMC11393150.

Kayan Tapan T, Çelebi F, Yaghouti K, Ağaçayak F, İlgün S, Soybir G, et al.; Ünal Ç, et al. The Relationship of Pathological Response and Visceral Muscle and Fat Volume in Women With Breast Cancer Who Received Neoadjuvant Chemotherapy. Eur J Breast Health. 2024;20(2):117-121. doi:10.4274/ejbh.galenos.2024.2023-12-5. PMID: 38571683; PMCID: PMC10985580.

Kurt S, İlgün AS, Özkurt E, Soybir G, Alço G, Ünal Ç, et al. Outcomes of reconstructive techniques in breast cancer using BCCT.core software. World J Surg Oncol. 2024;22(1):82. doi:10.1186/s12957-024-03343-3. PMID: 38519998; PMCID: PMC10960372.

Şenocak Taşçı E, Oyan B, Sönmez Ö, Mutlu AU, Atcı MM, Sakin A, et al.; Ünal Ç, et al. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer. BMC Cancer. 2024;24:16. doi:10.1186/s12885-023-11783-5.

Ünal Ç, Sağlam S. Metastatic neuroendocrine carcinoma: Liver metastases presenting with diffuse nodular calcifications on CT. J Cancer Res Ther. 2024;20(1):464-466. doi:10.4103/jcrt.jcrt_497_21. PMID: 38554365.

Ünal Ç, Sağlam S. Metronomic Temozolomide (mTMZ) and Bevacizumab—The Safe and Effective Frontier for Treating Metastatic Neuroendocrine Tumors (NETs): A Single-Center Experience. Cancers (Basel).2023;15(23):5688. doi:10.3390/cancers15235688. PMID: 38067391; PMCID: PMC10705735.

Akyildiz A, Guven DC, Ozluk AA, Ismayilov R, Mutlu E, Unal OU, et al.; Ünal Ç, et al. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey. Medicine (Baltimore). 2023;102(45):e35950. doi:10.1097/MD.0000000000035950. PMID: 37960746; PMCID: PMC10637501.

Ünal Ç, Selcuk NA, Biricik FS, Alan O, Ordu C, Selvi O, et al. Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye. Eurasian J Med Oncol. 2023;7(3):232-242. doi:10.14744/ejmo.2023.48337.

Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, et al.; Ünal Ç, et al. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2023;149(8):4141-4148. doi:10.1007/s00432-022-04252-2. PMID: 36048274.

Başoğlu T, Sakin A, Erol C, Özden E, Çabuk D, Çılbır E, et al.; Ünal Ç, et al. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish Oncology Group study. J Chemother. 2023;35(2):142-149. doi:10.1080/1120009X.2022.2073159. PMID: 35579894

Gürbüz M, Kutlu Y, Akkuş E, Köksoy EB, Köse N, Öven BB, et al.; Ünal Ç, et al. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group. J Cancer Res Clin Oncol. 2022;148(12):3547-3555. doi:10.1007/s00432-022-04087-x.

İlgün AS, Aktepe F, Gönüllü O, Kapucuoğlu N, Yararbaş K, Alço G, et al.; Ünal Ç, et al. The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer. Future Oncol.2022;18(29):3289-3298. doi:10.2217/fon-2022-0157.

Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, et al.; Ünal Ç, et al. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022;18(23):2573-2582. doi:10.2217/fon-2022-0083.

Pilanci KN, Ünal Ç, Ordu C, Gokmen E, Ozdogan M, Guler N, et al. Correlation between clinicopathologic factors and recurrence score according to TAILORx risk category in patients with hormone receptor-positive early-stage breast cancer. J BUON. 2021;26(6):2266-2273.

Ünal Ç. Kolon Kanserinde Geriatrik Hasta Yönetimi. In: Sedef AM, Akagündüz B, eds. Geriatrik Onkoloji.Ankara: Akademisyen Kitabevi; 2021. Bölüm 36, s.439-448. ISBN: 978-625-7679-79-4.

Ünal Ç. Yeni İlaçların Hedefi Olarak Onkogenler. In: Sedef AM, ed. Temel Onkoloji. Ankara: Akademisyen Kitabevi; 2020. Bölüm 24, s.173-182. ISBN: 978-625-727-518-7. doi:10.37609/akya.1765.

Ünal Ç, Sağlam S, Doğusoy G. Akciğer NET’e Yaklaşım. In: Özet A, Özdemir N, Yazıcı O, eds. Akciğer Kanseri.1. Baskı. Ankara: Türkiye Klinikleri; 2020. s.107-112.